Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In Kyprolis Label


Amgen announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and a variation to the marketing application to the European Medicines Agency to include overall survival data from the Phase 3 head-to-head ENDEAVOR trial in the product information for Kyprolis (carfilzomib).
Source link